AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17074625 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Pain Coping Inventory (CPCI)
Number of subjects: 250
Study 17074625 — intervention group
Group type: EXPERIMENTAL
Intervention: CPCI (65-item and 42-item versions)
Number of subjects: 250
Study 15650310 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with grass pollen
Number of subjects: 29
Study 12404199 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 10 mg
Number of subjects: 60
Study 12404199 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen (CEE) 0.625 mg
Number of subjects: 60
Study 12404199 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen transdermal patch (ETP) 50 microg
Number of subjects: 60
Study 12404199 — intervention group
Group type: COMPARATOR
Intervention: Dietetic advice (placebo group)
Number of subjects: 60
Study 10090431 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol maleate ophthalmic gel-forming solution 0.5% (timolol gel) once daily
Number of subjects: 202
Study 10090431 — intervention group
Group type: COMPARATOR
Intervention: Timolol maleate ophthalmic solution 0.5% (timolol solution) twice daily
Number of subjects: 202
Study 10090431 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 202
Study 7477219 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril
Number of subjects: 1749
Study 7477219 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1749
Study 2122715 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous feeding for 24 hours
Number of subjects: 18
Study 2122715 — intervention group
Group type: COMPARATOR
Intervention: Night feeding (from 1700 to 0900)
Number of subjects: 18
Study 354839 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone 25 mg
Number of subjects: 100
Study 354839 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone 50 mg
Number of subjects: 100
Study 354839 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone 75 mg
Number of subjects: 100
Study 354839 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone 12.5 mg
Number of subjects: 100
Study 354839 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 31866076 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance treatment (MT)
Number of subjects: 103
Study 31866076 — intervention group
Group type: COMPARATOR
Intervention: Dose-reduction/discontinuation (DR)
Number of subjects: 103
Study 31866076 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (not specified)
Number of subjects: 103
Study 31324734 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive systolic BP control (targeting <120 mm Hg)
Number of subjects: 8526
Study 31324734 — intervention group
Group type: COMPARATOR
Intervention: Standard systolic BP control (targeting <140 mm Hg)
Number of subjects: 8526
Study 31324734 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive systolic BP control
Number of subjects: 8526
Study 28938961 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP analysis using Roche Diagnostics Elecsys proBNPII immunoassay
Number of subjects: 1461
Study 28938961 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP analysis
Number of subjects: 1461
Study 25468164 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine follow-up
Number of subjects: 924
Study 25468164 — intervention group
Group type: COMPARATOR
Intervention: Self-assessment
Number of subjects: 924
Study 23357290 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftaroline
Number of subjects: 139
Study 23357290 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone
Number of subjects: 139
Study 21039893 — intervention group
Group type: EXPERIMENTAL
Intervention: Silk sutures
Number of subjects: 10
Study 21039893 — intervention group
Group type: COMPARATOR
Intervention: Teflon-coated polyester sutures
Number of subjects: 10
Study 19790150 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus with CNI reduction or discontinuation
Number of subjects: 145
Study 19790150 — intervention group
Group type: COMPARATOR
Intervention: Standard-exposure CNI
Number of subjects: 145
Study 17846353 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose VIT100 (0.75 mg)
Number of subjects: 175
Study 17846353 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose VIT100 (0.15 mg)
Number of subjects: 175
Study 17846353 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 175
Study 17846353 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (all groups)
Number of subjects: 175
Study 15475528 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial indomethacin (to inhibit cyclooxygenase products)
Number of subjects: 16
Study 15475528 — intervention group
Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 16
Study 15475528 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial aminophylline (to block adenosine receptors)
Number of subjects: 16
Study 11915776 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO
Number of subjects: 26
Study 11915776 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO-PRO
Number of subjects: 26
Study 11915776 — intervention group
Group type: COMPARATOR
Intervention: P
Number of subjects: 26
Study 10023283 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 30 mg
Number of subjects: 90
Study 10023283 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 2 mg
Number of subjects: 90
Study 10023283 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 90
Study 8072818 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalent pneumococcal capsular polysaccharide (CPS)‐protein conjugate vaccines with serotypes 6A and 23F
Number of subjects: 118
Study 8072818 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalent pneumococcal conjugate vaccine with native CPS directly linked to the carrier protein
Number of subjects: 118
Study 8072818 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalent pneumococcal conjugate vaccines with smaller CPS or a six‐carbon linker
Number of subjects: 118
Study 8072818 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugation of two pneumococcal CPSs
Number of subjects: 118
Study 8072818 — intervention group
Group type: EXPERIMENTAL
Intervention: Characteristics of the CPS and CPS‐protein linkage
Number of subjects: 118
Study 8072818 — intervention group
Group type: COMPARATOR
Intervention: Licensed pneumococcal vaccine
Number of subjects: 118
Study 3186274 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg naloxone i.v.
Number of subjects: 24
Study 3186274 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg naloxone i.v.
Number of subjects: 24
Study 3186274 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 29064900 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic mesh in the sublay position
Number of subjects: 232
Study 29064900 — intervention group
Group type: COMPARATOR
Intervention: No mesh (control group)
Number of subjects: 232
Study 28686535 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 134
Study 28686535 — intervention group
Group type: EXPERIMENTAL
Intervention: PET-CT
Number of subjects: 134
Study 28686535 — intervention group
Group type: EXPERIMENTAL
Intervention: PET-CT normalization after three cycles of RVD
Number of subjects: 134
Study 28686535 — intervention group
Group type: EXPERIMENTAL
Intervention: PET-CT normalization before maintenance therapy
Number of subjects: 134
Study 28686535 — intervention group
Group type: EXPERIMENTAL
Intervention: Extramedullary disease at diagnosis
Number of subjects: 134
Study 28686535 — intervention group
Group type: EXPERIMENTAL
Intervention: PET-CT normalization before maintenance
Number of subjects: 134
Study 25483563 — intervention group
Group type: COMPARATOR
Intervention: PPC-5650
Number of subjects: 25
Study 25483563 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 23782709 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized, meridian‐based syndrome differentiation and Sa‐am acupuncture treatment
Number of subjects: 250
Study 23782709 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard acupuncture treatment
Number of subjects: 250
Study 23782709 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture treatment
Number of subjects: 250
Study 23782709 — intervention group
Group type: COMPARATOR
Intervention: No acupuncture treatment
Number of subjects: 250
Study 21895884 — intervention group
Group type: EXPERIMENTAL
Intervention: rasagiline 1 mg/day
Number of subjects: 105
Study 21895884 — intervention group
Group type: COMPARATOR
Intervention: entacapone 200 mg with each levodopa dose
Number of subjects: 105
Study 19108956 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Dose Alcohol (0.33 ml alcohol/kg body weight)
Number of subjects: 334
Study 19108956 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate Dose Alcohol (0.75 ml/kg)
Number of subjects: 334
Study 19108956 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 334
Study 19108956 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 334
Study 16414441 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume hemodiafiltration (HDF)
Number of subjects: 22
Study 16414441 — intervention group
Group type: COMPARATOR
Intervention: High-flux hemodialysis (HD)
Number of subjects: 22
Study 15319613 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone interview
Number of subjects: 719
Study 15319613 — intervention group
Group type: COMPARATOR
Intervention: Mail interview followed by telephone interview
Number of subjects: 719
Study 11763935 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.03% triclosan mouthrinse (15 ml, twice daily for 21 days)
Number of subjects: 21
Study 11763935 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouthrinse (15 ml, twice daily for 21 days)
Number of subjects: 21
Study 11763935 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.03% triclosan mouthrinse
Number of subjects: 21
Study 9487838 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonicare
Number of subjects: 66
Study 9487838 — intervention group
Group type: COMPARATOR
Intervention: Braun
Number of subjects: 66
Study 8225695 — intervention group
Group type: EXPERIMENTAL
Intervention: silybin 240 mg b.i.d.
Number of subjects: 20
Study 8225695 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study 3544654 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoxetine 600 mg
Number of subjects: 10
Study 3544654 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 29577381 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple fixed cameras
Number of subjects: 36
Study 29577381 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone
Number of subjects: 36
Study 29577381 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional audio with live US stream
Number of subjects: 36
Study 29577381 — intervention group
Group type: COMPARATOR
Intervention: Instructional video
Number of subjects: 36
Study 29577381 — intervention group
Group type: COMPARATOR
Intervention: No instructional video
Number of subjects: 36
Study 26647971 — intervention group
Group type: EXPERIMENTAL
Intervention: THC (Δ(9)‐tetrahydrocannabinol)
Number of subjects: 78
Study 26647971 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 25491026 — intervention group
Group type: EXPERIMENTAL
Intervention: MOVI-2 intervention (play-based and non-competitive activities)
Number of subjects: 712
Study 25491026 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 712
Study 21840138 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil 200mg
Number of subjects: 210
Study 21840138 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil 400mg
Number of subjects: 210
Study 21840138 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study 21840138 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (200mg and 400mg combined)
Number of subjects: 210
Study 20022600 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin injection
Number of subjects: 100
Study 20022600 — intervention group
Group type: COMPARATOR
Intervention: Normal saline injection
Number of subjects: 100
Study 18695158 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbidopa-levodopa 37.5/150 mg daily
Number of subjects: 361
Study 18695158 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbidopa-levodopa 75/300 mg daily
Number of subjects: 361
Study 18695158 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbidopa-levodopa 150/600 mg daily
Number of subjects: 361
Study 18695158 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 361
Study 15374865 — intervention group
Group type: EXPERIMENTAL
Intervention: Hotelling's T2 statistic
Number of subjects: 0
Study 15374865 — intervention group
Group type: COMPARATOR
Intervention: Univariate procedure
Number of subjects: 0
Study 14583179 — intervention group
Group type: COMPARATOR
Intervention: Serum and urine NO levels in microalbuminurics
Number of subjects: 98
Study 14583179 — intervention group
Group type: COMPARATOR
Intervention: Serum and urine NO levels in normoalbuminurics
Number of subjects: 98
Study 14583179 — intervention group
Group type: COMPARATOR
Intervention: Hyperfiltration in normoalbuminurics
Number of subjects: 98
Study 14583179 — intervention group
Group type: COMPARATOR
Intervention: Hyperfiltration in microalbuminurics
Number of subjects: 98
Study 14583179 — intervention group
Group type: COMPARATOR
Intervention: Plasma MDA levels in microalbuminurics
Number of subjects: 98
Study 14583179 — intervention group
Group type: COMPARATOR
Intervention: Plasma MDA levels in normoalbuminurics
Number of subjects: 98
Study 14583179 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum glucose correlation in microalbuminurics
Number of subjects: 98
Study 14583179 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum NO levels correlation in normoalbuminurics
Number of subjects: 98
Study 14583179 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum NO levels correlation in microalbuminurics
Number of subjects: 98
Study 14583179 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c levels correlation in normoalbuminurics
Number of subjects: 98
Study 11463592 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory pressure support ventilation (PSV)
Number of subjects: 52
Study 11463592 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous breathing trials (SB)
Number of subjects: 52
Study 11463592 — intervention group
Group type: COMPARATOR
Intervention: Historical control patients (uncontrolled clinical practice)
Number of subjects: 52
Study 9753211 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 0.1 mg/Kg intravenously
Number of subjects: 168
Study 9753211 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 0.2 mg/Kg intravenously
Number of subjects: 168
Study 9753211 — intervention group
Group type: COMPARATOR
Intervention: 0.07 mg/Kg diazepam orally
Number of subjects: 168
Study 9753211 — intervention group
Group type: COMPARATOR
Intervention: No premedication
Number of subjects: 168
Study 8184348 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical surgery
Number of subjects: 105
Study 8184348 — intervention group
Group type: COMPARATOR
Intervention: Debridement surgery
Number of subjects: 105
Study 3110315 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinidazole (2 g preoperative oral dose)
Number of subjects: 0
Study 3110315 — intervention group
Group type: COMPARATOR
Intervention: Pivampicillin (high-dose short-term broad spectrum penicillin)
Number of subjects: 0
Study 31028900 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper-limb robotic-assisted therapy (RAT)
Number of subjects: 45
Study 31028900 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 45
Study 29166223 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminiscence intervention (10 sessions)
Number of subjects: 160
Study 29166223 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 160
Study 24288364 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (10 mg/d) plus telmisartan (80 mg/d)
Number of subjects: 151
Study 24288364 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (10 mg/d) plus irbesartan (300 mg/d)
Number of subjects: 151
Study 24288364 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (10 mg/d) plus olmesartan (20 mg/d)
Number of subjects: 151
Study 24288364 — intervention group
Group type: COMPARATOR
Intervention: Control group (telmisartan, irbesartan, olmesartan)
Number of subjects: 151
Study 23454151 — intervention group
Group type: EXPERIMENTAL
Intervention: Ureteroscopy in neurogenic bladder patients
Number of subjects: 20
Study 23454151 — intervention group
Group type: COMPARATOR
Intervention: Ureteroscopy in controls
Number of subjects: 20
Study 21399485 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil (5 to 10 mg/d) for 6 months
Number of subjects: 529
Study 18685810 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 81 mg daily
Number of subjects: 49
Study 18685810 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 100 mg every other day
Number of subjects: 49
Study 16520442 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 22
Study 16520442 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 15486837 — intervention group
Group type: EXPERIMENTAL
Intervention: artesunate plus mefloquine
Number of subjects: 330
Study 15486837 — intervention group
Group type: EXPERIMENTAL
Intervention: artemether-lumefantrine
Number of subjects: 330
Study 15486837 — intervention group
Group type: COMPARATOR
Intervention: chloroquine plus sulfadoxine-pyrimethamine
Number of subjects: 330
Study 10960017 — intervention group
Group type: EXPERIMENTAL
Intervention: Enamel matrix proteins (EMP)
Number of subjects: 21
Study 10960017 — intervention group
Group type: COMPARATOR
Intervention: Enamel matrix proteins combined with bovine porous bone mineral (EMP/BPBM)
Number of subjects: 21
Study 9181906 — intervention group
Group type: EXPERIMENTAL
Intervention: Nephrectomy plus preoperative subcutaneous immunotherapy with IL-2 (18 million IU/day for 3 days)
Number of subjects: 20
Study 9181906 — intervention group
Group type: EXPERIMENTAL
Intervention: Nephrectomy plus preoperative subcutaneous immunotherapy with IL-2
Number of subjects: 20
Study 9181906 — intervention group
Group type: COMPARATOR
Intervention: Nephrectomy alone (Control)
Number of subjects: 20
Study 8436025 — intervention group
Group type: EXPERIMENTAL
Intervention: Attributional intervention
Number of subjects: 101
Study 8436025 — intervention group
Group type: COMPARATOR
Intervention: Attention training program
Number of subjects: 101
Study 8436025 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control group
Number of subjects: 101
Study 31965842 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplement (Bifidobacterium infantis R0033, Bifidobacterium bifidum R0071, and Lactobacillus helveticus R0052)
Number of subjects: 132
Study 31965842 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study 31965842 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplement
Number of subjects: 132
Study 28562458 — intervention group
Group type: EXPERIMENTAL
Intervention: Flipped model (FC)
Number of subjects: 318
Study 28562458 — intervention group
Group type: COMPARATOR
Intervention: Traditional model (TC)
Number of subjects: 318
Study 24906541 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet plus pravastatin
Number of subjects: 7832
Study 24906541 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal fasting glucose (AFG) plus high triglycerides (TGs)
Number of subjects: 7832
Study 24906541 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal fasting glucose (AFG) alone
Number of subjects: 7832
Study 24906541 — intervention group
Group type: EXPERIMENTAL
Intervention: High triglycerides (TGs) alone
Number of subjects: 7832
Study 24906541 — intervention group
Group type: COMPARATOR
Intervention: Normal fasting glucose plus normal TGs (reference group)
Number of subjects: 7832
Study 22730929 — intervention group
Group type: EXPERIMENTAL
Intervention: LPV/r+RAL
Number of subjects: 206
Study 22730929 — intervention group
Group type: COMPARATOR
Intervention: LPV/r+TDF/FTC
Number of subjects: 206
Study 21716146 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine 1200 mg/m on days 1 and 8 every 21 days (Arm A)
Number of subjects: 146
Study 21716146 — intervention group
Group type: COMPARATOR
Intervention: Erlotinib 150 mg daily (Arm B)
Number of subjects: 146
Study 21716146 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine 1000 mg/m on days 1 and 8 every 21 days and erlotinib 100 mg daily (Arm C)
Number of subjects: 146
Study 18294489 — intervention group
Group type: COMPARATOR
Intervention: NYHA functional class I
Number of subjects: 14703
Study 18294489 — intervention group
Group type: EXPERIMENTAL
Intervention: NYHA functional class II
Number of subjects: 14703
Study 18294489 — intervention group
Group type: EXPERIMENTAL
Intervention: NYHA functional class III
Number of subjects: 14703
Study 17313002 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture at Hegu (LI 4) and intravenous drip of oxytocin
Number of subjects: 276
Study 17313002 — intervention group
Group type: COMPARATOR
Intervention: Intravenous drip of oxytocin
Number of subjects: 276
Study 14641801 — intervention group
Group type: EXPERIMENTAL
Intervention: PPARD +294C allele
Number of subjects: 1740
Study 14641801 — intervention group
Group type: EXPERIMENTAL
Intervention: Homozygous C-allele carriers
Number of subjects: 1740
Study 14641801 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene-gene interaction involving PPARD polymorphism and PPAR alpha L162V polymorphism
Number of subjects: 1740
Study 11053823 — intervention group
Group type: EXPERIMENTAL
Intervention: Median sternotomy with CPB
Number of subjects: 40
Study 11053823 — intervention group
Group type: EXPERIMENTAL
Intervention: Median sternotomy and off-pump
Number of subjects: 40
Study 11053823 — intervention group
Group type: EXPERIMENTAL
Intervention: Minithoracotomy with CPB
Number of subjects: 40
Study 11053823 — intervention group
Group type: EXPERIMENTAL
Intervention: Minithoracotomy and off-pump
Number of subjects: 40
Study 11053823 — intervention group
Group type: EXPERIMENTAL
Intervention: All procedures
Number of subjects: 40
Study 9365351 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects without disc herniation (33 subjects)
Number of subjects: 60